U.S. markets open in 3 hours 49 minutes
  • S&P Futures

    3,755.75
    -9.75 (-0.26%)
     
  • Dow Futures

    30,815.00
    -63.00 (-0.20%)
     
  • Nasdaq Futures

    12,398.50
    -56.50 (-0.45%)
     
  • Russell 2000 Futures

    2,135.30
    -9.20 (-0.43%)
     
  • Crude Oil

    65.11
    +1.28 (+2.01%)
     
  • Gold

    1,692.60
    -8.10 (-0.48%)
     
  • Silver

    25.30
    -0.16 (-0.63%)
     
  • EUR/USD

    1.1937
    -0.0041 (-0.35%)
     
  • 10-Yr Bond

    1.5500
    0.0000 (0.00%)
     
  • Vix

    28.36
    +1.69 (+6.34%)
     
  • GBP/USD

    1.3801
    -0.0093 (-0.67%)
     
  • USD/JPY

    108.5120
    +0.5360 (+0.50%)
     
  • BTC-USD

    47,036.17
    -2,021.23 (-4.12%)
     
  • CMC Crypto 200

    941.51
    -45.70 (-4.63%)
     
  • FTSE 100

    6,654.95
    +4.07 (+0.06%)
     
  • Nikkei 225

    28,864.32
    -65.79 (-0.23%)
     

Why Sorrento And Infinity Are Moving Today

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Tanzeel Akhtar
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Sorrento Therapeutics (NASDAQ: SRNE) shares are trading higher on Wednesday after the company announced it has received CLIA Licensure from the State of California that permits testing of clinical samples.

Sorrento Therapeutics is a biotechnology company focused on the development of novel immunotherapies for oncology and autoimmune/inflammation diseases.

Sorrento Therapeutics shares were trading up 4.81% at $8.28 at the time of publication. The stock has a 52-week high of $19.39 and a 52-week low of $1.55.

Infinity Pharmaceuticals (NASDAQ: INFI) shares are trading lower after the company announced the presentation of front-line triple-negative breast cancer data from its ongoing Phase 2 Mario-3 trial at the 2020 San Antonio Breast Cancer Symposium.

Infinity Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. Infinity has a strategic partnership with AbbVie to develop some of its oncology-related treatments. The company operates in only one segment which is drug development.

Infinity Pharmaceuticals shares were trading down 17.15% at $2.30. The stock has a 52-week high of $3.13 and a 52-week low of 60 cents.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.